# Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

> **NCT07008469** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Avidity Biosciences, Inc.** · enrollment: 230 (estimated)

## Conditions studied

- Myotonic Dystrophy Type 1
- DM1
- Myotonic Dystrophy
- Myotonia
- Myotonic Dystrophy 1
- Myotonic Disorders
- Steinert Myotonic Dystrophy
- Steinert Disease

## Interventions

- **DRUG:** Del-desiran (AOC 1001)

## Key facts

- **NCT ID:** NCT07008469
- **Lead sponsor:** Avidity Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-07-25
- **Primary completion:** 2030-08
- **Final completion:** 2030-10
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07008469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07008469, "Global Open-Label Extension Study of Del-desiran for the Treatment of DM1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07008469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*